The use of GLP-1 receptor agonists (GLP-1 RAs) was associated with a lower risk for serious infections — particularly respiratory, skin and soft tissue, musculoskeletal, and vascular infections as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback